| Autor: |
Hope, Denise L., Woods, Phillip, Mey, Amary, Kelly, Fiona S., Townshend, James, Baumann‐Birkbeck, Lyndsee M., King, Michelle A. |
| Zdroj: |
International Journal of Pharmacy Practice; Jun2020, Vol. 28 Issue 3, p246-254, 9p, 4 Charts |
| Abstrakt: |
Objectives: Reclassification of medicines from prescription to non‐prescription increases timely access to treatment, promotes self‐management of minor ailments and relieves healthcare system burden. Previous research identified that Australia lagged behind the United Kingdom and New Zealand in medicines reclassification. This study aimed to identify Australian pharmacists' opinions on the current state of medicines reclassification; the prescription medicines consumers requested without prescription; the medicines pharmacists believed should and should not be considered for reclassification; and perceived barriers to reclassification. Methods: A 2016 national online survey that sought pharmacists' opinions on the state of reclassification, perceived barriers to reclassification and readiness of the profession for further reclassification. Pharmacists' comments were invited through open‐ended questions. Key findings: Two hundred and thirty‐five valid surveys were completed. Respondents practised in community, hospital, consultant and academic contexts, and the majority were female (58.7%, n = 138). More than two thirds (70.66%, n = 166) of pharmacists reported receiving daily or weekly requests for non‐prescription access to prescription medicines. The majority of pharmacists (71.7%) agreed that the Australian pharmacy profession is ready for further medicines reclassification, guided by patient safety, harm minimisation and medication continuance. The most prominent barrier to further reclassification was opposition from other healthcare professionals. Conclusions: Australian pharmacists believe that their profession has the capacity to safely and effectively manage a wider range of non‐prescription medicines through increased reclassification in the contexts of patient safety and risk mitigation. This study has contributed to the global conversation on non‐prescription medicines access, providing momentum for practice and policy change. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text